These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 32649330)

  • 21. The Naloxone Component of Buprenorphine/Naloxone: Discouraging Misuse, but at What Cost?
    Gregg J; Hartley J; Lawrence D; Risser A; Blazes C
    J Addict Med; 2023 Jan-Feb 01; 17(1):7-9. PubMed ID: 35913990
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.
    Magnelli F; Biondi L; Calabria R; Fiore A; Peluso E; Vonella D; Rota AG
    Clin Drug Investig; 2010; 30 Suppl 1():21-6. PubMed ID: 20450242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
    Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
    Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient opinion and acceptance of emergency department buprenorphine/naloxone to-go home initiation packs.
    Duncan K; Scheuermeyer F; Lane D; Ahamad K; Moe J; Dong K; Nolan S; Buxton J; Miles I; Johnson C; Christenson J; Whyte M; Daoust R; Garrod E; Badke K; Kestler A
    CJEM; 2023 Oct; 25(10):802-807. PubMed ID: 37606738
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Challenges with buprenorphine inductions in the context of the fentanyl overdose crisis: A case series.
    Shearer D; Young S; Fairbairn N; Brar R
    Drug Alcohol Rev; 2022 Feb; 41(2):444-448. PubMed ID: 34647379
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of acute naloxone-precipitated opioid withdrawal with buprenorphine.
    Chhabra N; Aks SE
    Am J Emerg Med; 2020 Mar; 38(3):691.e3-691.e4. PubMed ID: 31753622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Buprenorphine alone or with naloxone: Which is safer?
    Kelty E; Cumming C; Troeung L; Hulse G
    J Psychopharmacol; 2018 Mar; 32(3):344-352. PubMed ID: 29433352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-dose tramadol conversion to buprenorphine-naloxone.
    Kirk JK; Boyd CT; Cassidy-Vu L; McRae LP; Strickland HE; Fagan EB
    J Opioid Manag; 2023; 19(2):187-190. PubMed ID: 37270427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Methadone to buprenorphine/naloxone induction without withdrawal utilizing transdermal fentanyl bridge in an inpatient setting-Azar method.
    Azar P; Nikoo M; Miles I
    Am J Addict; 2018 Dec; 27(8):601-604. PubMed ID: 30387894
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Opioid-induced respiratory effects: new data on buprenorphine.
    Dahan A
    Palliat Med; 2006; 20 Suppl 1():s3-8. PubMed ID: 16764215
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-dose overlap initiation with split tablets of buprenorphine in intubated intensive care unit patients with opioid use disorder.
    Szczesniak L; Britton S; Rn TB; Sullivan R
    Harm Reduct J; 2024 Jun; 21(1):114. PubMed ID: 38849912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low dose IV buprenorphine inductions for patients with opioid use disorder and concurrent pain: a retrospective case series.
    Murray JP; Pucci G; Weyer G; Ari M; Dickson S; Kerins A
    Addict Sci Clin Pract; 2023 Jun; 18(1):38. PubMed ID: 37264449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
    Webster L; Hjelmström P; Sumner M; Gunderson EW
    J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. "Macrodosing" Sublingual Buprenorphine and Extended-release Buprenorphine in a Hospital Setting: 2 Case Reports.
    Kahan M; Marion-Bellemare L; Samson J; Srivastava A
    J Addict Med; 2023 Jul-Aug 01; 17(4):485-487. PubMed ID: 37579117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Buprenorphine to reverse respiratory depression from methadone overdose in opioid-dependent patients: a prospective randomized trial.
    Zamani N; Buckley NA; Hassanian-Moghaddam H
    Crit Care; 2020 Feb; 24(1):44. PubMed ID: 32033582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Case report: Successful induction of buprenorphine/naloxone using a microdosing schedule and assertive outreach.
    Rozylo J; Mitchell K; Nikoo M; Durante SE; Barbic SP; Lin D; Mathias S; Azar P
    Addict Sci Clin Pract; 2020 Jan; 15(1):2. PubMed ID: 31941547
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of the newer class of opioid antagonists in pregnancy.
    Poon S; Pupco A; Koren G; Bozzo P
    Can Fam Physician; 2014 Jul; 60(7):631-2, e348-9. PubMed ID: 25022635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Course and treatment of buprenorphine/naloxone withdrawal: an analysis of case reports.
    Westermeyer J; McCance-Katz EF
    Am J Addict; 2012; 21(5):401-3. PubMed ID: 22882389
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of kratom dependence with buprenorphine/naloxone in a veteran population.
    Lei J; Butz A; Valentino N
    Subst Abus; 2021; 42(4):497-502. PubMed ID: 33617752
    [No Abstract]   [Full Text] [Related]  

  • 40. Acute pain control challenges with buprenorphine/naloxone therapy in a patient with compartment syndrome secondary to McArdle's disease: a case report and review.
    McCormick Z; Chu SK; Chang-Chien GC; Joseph P
    Pain Med; 2013 Aug; 14(8):1187-91. PubMed ID: 23647815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.